NCT02077114

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Herlev Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess whether a vaccine containing a small fragment of the protein IDO, which may be present in cancer cells and cells of the immune system, is safe to use in combination with either Ipilimumab or Vemurafenib in the treatment of malignant melanoma that has metastasized.

Conditions

• Malignant Melanoma With Metastasis

Interventions

Type	Name	Description
BIOLOGICAL	Vaccine consisting of a peptide derived from the protein IDO	All patients will receive seven vaccines containing IDOlong

Timeline

• Start date: 2014-02-01
• Primary completion: 2014-09-01
• First posted: 2014-03-04
• Last updated: 2014-09-26

Locations

1 site across 1 country: Denmark